These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83 related articles for article (PubMed ID: 6696942)
21. Adherence of lysostaphin to and penetration into human monocytes. van den Broek PJ; Buys LF; van Furth R Scand J Immunol; 1985 Feb; 21(2):189-93. PubMed ID: 3975574 [TBL] [Abstract][Full Text] [Related]
22. Effect of various blood culture media on lysostaphin sensitivity of staphylococci. Severance PJ; Kauffman CA; Sheagren JN J Clin Microbiol; 1980 Nov; 12(5):709-10. PubMed ID: 7276143 [TBL] [Abstract][Full Text] [Related]
23. Lysostaphin as a potential therapeutic agent for staphylococcal biofilm eradication. Walencka E; Sadowska B; Rozalska S; Hryniewicz W; Rózalska B Pol J Microbiol; 2005; 54(3):191-200. PubMed ID: 16450834 [TBL] [Abstract][Full Text] [Related]
24. Potent, synergistic inhibition of Staphylococcus aureus upon exposure to a combination of the endopeptidase lysostaphin and the cationic peptide ranalexin. Graham S; Coote PJ J Antimicrob Chemother; 2007 Apr; 59(4):759-62. PubMed ID: 17324959 [TBL] [Abstract][Full Text] [Related]
25. [Effect of the composition of the reversion medium on the transformation of coccal forms and L-form of Staphylococcus aureus lysostaphin protoplasts]. Kato Y; Hirachi Y; Toda Y; Kurono M; Takemasa N; Kotani S Osaka Daigaku Shigaku Zasshi; 1985 Dec; 30(2):296-303. PubMed ID: 3869230 [No Abstract] [Full Text] [Related]
26. In vitro activity of lysostaphin, mupirocin, and tea tree oil against clinical methicillin-resistant Staphylococcus aureus. LaPlante KL Diagn Microbiol Infect Dis; 2007 Apr; 57(4):413-8. PubMed ID: 17141452 [TBL] [Abstract][Full Text] [Related]
27. Efficient production of Staphylococcus simulans lysostaphin in a benchtop bioreactor by recombinant Escherichia coli. Szweda P; Gorczyca G; Filipkowski P; Zalewska M; Milewski S Prep Biochem Biotechnol; 2014; 44(4):370-81. PubMed ID: 24320237 [TBL] [Abstract][Full Text] [Related]
31. Effects of lysostaphin on Staphylococcus aureus infections of the mouse mammary gland. Bramley AJ; Foster R Res Vet Sci; 1990 Jul; 49(1):120-1. PubMed ID: 2382049 [TBL] [Abstract][Full Text] [Related]
35. Rapid solid-phase radioassay for staphylococcal protein A. Dickie N; Konowalchuk J Can J Microbiol; 1977 Jun; 23(6):832-4. PubMed ID: 871976 [TBL] [Abstract][Full Text] [Related]
36. Antibody-directed targeting of lysostaphin adsorbed onto polylactide nanoparticles increases its antimicrobial activity against S. aureus in vitro. Satishkumar R; Vertegel AA Nanotechnology; 2011 Dec; 22(50):505103. PubMed ID: 22107797 [TBL] [Abstract][Full Text] [Related]
37. The addition of lysostaphin dramatically improves survival, protects porcine biomesh from infection, and improves graft tensile shear strength. Belyansky I; Tsirline VB; Martin TR; Klima DA; Heath J; Lincourt AE; Satishkumar R; Vertegel A; Heniford BT J Surg Res; 2011 Dec; 171(2):409-15. PubMed ID: 21696759 [TBL] [Abstract][Full Text] [Related]
38. [Topical use of lysostaphin for Staphylococcus aureus infection of burn wounds in mice]. Huan JN Zhonghua Wai Ke Za Zhi; 1992 May; 30(5):270-1, 316. PubMed ID: 1289000 [TBL] [Abstract][Full Text] [Related]
39. In vivo efficacy of the antimicrobial peptide ranalexin in combination with the endopeptidase lysostaphin against wound and systemic meticillin-resistant Staphylococcus aureus (MRSA) infections. Desbois AP; Gemmell CG; Coote PJ Int J Antimicrob Agents; 2010 Jun; 35(6):559-65. PubMed ID: 20206480 [TBL] [Abstract][Full Text] [Related]